Perrigo confirms patent challenge for generic version of Soolantraź cream, 1%
Perrigo announced its subsidiary has filed a Paragraph IV ANDA with the FDA for a generic version of Soolantraź (ivermectin) cream, 1%. Following notification, Galderma Labs, Galderma, and Nestle Skin Health, filed a patent litigation suit asserting patents listed in the Orange Book for Soolantraź. July 17, 2017